Comparative Pharmacology
Head-to-head clinical analysis: FERRIC CITRATE versus VELPHORO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FERRIC CITRATE versus VELPHORO.
FERRIC CITRATE vs VELPHORO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ferric citrate dissociates to provide ferric iron, which binds dietary phosphate in the gastrointestinal tract, forming insoluble ferric phosphate that is excreted in feces, thereby reducing serum phosphate levels. It also provides iron for erythropoiesis.
Iron-based phosphate binder that forms non-absorbable complexes with dietary phosphate in the gastrointestinal tract, reducing serum phosphate levels.
1-2 tablets (210-420 mg elemental iron) orally three times daily with meals.
1-2 tablets (500-1000 mg iron) orally three times daily with meals; titrate to achieve serum phosphorus target.
None Documented
None Documented
Approximately 6 hours for absorbed iron; clinical effect on serum phosphate occurs within 1–2 weeks.
Not applicable (non-absorbed drug acting locally in GI tract; no systemic half-life).
Primarily fecal as unabsorbed iron (≥90%); minimal renal excretion (<1%) of absorbed iron.
Primarily fecal as unabsorbed drug; negligible renal excretion (<0.1%).
Category C
Category C
Phosphate Binder
Phosphate Binder